Base de datos : IBECS
Búsqueda : D08.811.277.656.350.350.126 [Categoria DeCS]
Referencias encontradas : 18 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 2 va a la página        

  1 / 18 IBECS  
              next record last record
selecciona
para imprimir
Fotocópia
Texto completo
Id: 191213
Autor: Pérez Pérez, Antonio; Miñambres Donaire, Inka.
Título: Tratamiento de la hiperglucemia en el paciente con diabetes tipo 2 e hígado graso no alcohólico / Treatment of hyperglycemia in patients with type 2 diabetes and non-alcoholic fatty liver disease
Fuente: Endocrinol. diabetes nutr., Supl. (Ed. impr.);1(supl.2):28-33, sept. 2017. graf, tab.
Idioma: es.
Resumen: El enfoque del tratamiento farmacológico de la hiperglucemia en los pacientes con diabetes tipo 2 ha cambiado considerablemente en los últimos años. Un elemento clave es la individualización a la hora de establecer una terapia y considerar tanto las características del paciente y de la diabetes como los beneficios y los riesgos potenciales de la terapia. La existencia de hígado graso no alcohólico (HGNA) en un paciente con diabetes mellitus tipo 2 identifica un subgrupo de pacientes metabólicamente complejos y con mayor riesgo de desarrollar complicaciones cardiovasculares y microangiopáticas. Además, la diabetes es un marcador de la progresión del HGNA. Todo ello condiciona que el tratamiento de estos pacientes resulte un reto y represente un escenario clínico que justifique la utilización de opciones terapéuticas específicas. En el presente artículo revisaremos los datos disponibles sobre los efectos de los distintos fármacos hipoglucemiantes sobre el HGNA y las alteraciones metabólicas asociadas, y la estrategia para su selección en los pacientes con diabetes mellitus tipo 2 y HGNA

The focus of pharmacological treatment of hyperglycemia in patients with type 2 diabetes has changed considerably in recent years. Individualisation is a key element when establishing a therapy, considering both the patient's characteristics and diabetes as well as the potential benefits and risks of therapy. Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) constitute a subset of metabolically complex patients with a higher risk of developing cardiovascular and microangiopathic complications. Moreover, diabetes is a marker of progression of NAFLD. All these factors pose a challenge to the treatment of these patients and represent a clinical scenario that justifies the use of specific therapeutic options. In the present article, we review the available data on the effects of the different hypoglycaemic drugs on NAFLD and associated metabolic alterations, and the strategy for their selection in patients with type 2 diabetes and NAFLD
Responsable: ES1.1
BNCS


  2 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Id: 178907
Autor: Murgia, Antonio; Caboni, Pierluigi; Cadoni, Erika; Serra, Monica; Marongiu, Fabio; Laconi, Ezio.
Título: A GC-MS untargeted metabolomics analysis in the plasma and liver of rats lacking dipeptidyl-peptidase type IV enzyme activity
Fuente: J. physiol. biochem;73(4):575-582, nov. 2017. ilus, tab, graf.
Idioma: en.
Resumen: This study was achieved with the aim to find metabolic changes between Fischer rats with different dipeptidyl peptidase-type 4 (DPPIV) expression. The DPPIV is an enzyme expressed in several tissues and is critically involved in the regulation of meal-related insulin secretion in healthy individuals. The metabolic consequences of chronic DPPIV inhibition were analyzed in a surrogate animal model of genetic enzyme deficiency. Hyphenated gas chromatographyûmass spectrometry (GC-MS) and multivariate data analysis techniques were used to study the metabolic aqueous fraction profile of 18 plasma and liver samples in two syngeneic rat strains differing in DPPIV activity (DPPIV+ vs. DPPIV-). The hyperglycemic response following oral glucose administration was attenuated in DPPIV- rats, as expected. Statistical significant differences between the two strains were observed among the low molecular weight polar metabolites analyzed from plasma and liver. These included a decrease in malic acid and glutamine and an increase in pyroglutamic acid, serine, and alanine in plasma of DPPIV- rats. In addition, palmitic acid, l-proline, and ribitol were decreased in the liver of DPPIV- strain. Such alterations were compatible with a normal phenotype. These results suggest that long-term exposure to DPPIV inhibitors looks compatible with an overall balanced metabolism

No disponible
Responsable: ES1.1
BNCS


  3 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Texto completo
Id: 173570
Autor: Nieto-Fontarigo, JJ; González-Barcala, FJ; San-José, ME; Cruz, MJ; Linares, T; Soto-Mera, MT; Valdés-Cuadrado, L; García-González, MA; Andrade-Bulos, LJ; Arias, P; Nogueira, M; Salgado, FJ.
Título: Expansion of a CD26 low effector TH subset and reduction in circulating levels of sCD26 in stable allergic asthma in adults
Fuente: J. investig. allergol. clin. immunol;28(2):113-125, 2018. tab, graf, ilus.
Idioma: en.
Resumen: Background: The pathogenesis of asthma is dependent on the balance between regulatory and effector T cells, which display differential expression of CD25 and CD26. Therefore, alteration of circulating levels of sCD25 and sCD26 during allergic asthma could be conditioned by changes in leukocyte phenotype. Objectives: To analyze expression of CD25 and CD26 on T lymphocytes and their soluble derivatives (sCD25, sCD26) during stable phases of moderate-severe allergic asthma. Methods: Cross-sectional study with 2 adult cohorts of allergic asthmatics. Clinical, anthropometric, pulmonary, hematological, and biochemical parameters were measured. Phenotyping was performed with flow cytometry in both circulating and cultured leukocytes. Dipeptidyl peptidase 4 (DPP4) activity was assayed in culture supernatants. Results: In vitro studies revealed upregulation of CD26 on human T lymphocytes upon activation, especially under TH17-favoring conditions, and a correlation with soluble DPP4 activity (rs=0.641; P<.001). CD26 expression on lymphocytes was higher in asthmatics, while serum sCD26 was lower in women and patients. The latter finding could be associated with an expanded CD25 low/CD26 low /CD127 low subset of effector CD4 + T cells in allergic asthma, with no changes in Treg percentages. However, women showed an increased Teff/Treg ratio, which could explain their greater susceptibility to asthma. Conclusions: Allergic asthma causes an increment in CD25 low CD26Low helper T cells detected in stable stages. These changes are mirrored in serum and should be considered in the light of the downmodulating role of CD26 in major chemokines related to the pathogenesis of asthma such as CCL11 (eotaxin), CCL5 (RANTES), and CXCL12a (SDF-1alfa) (AU)

Introducción: La patogénesis del asma depende del equilibrio entre células T reguladoras y T efectoras, las cuales presentan distintos niveles de CD25 y CD26. Por tanto, la alteración de la concentración de sCD25 y sCD26 durante el asma alérgica podría estar condicionada por cambios en el fenotipo de los leucocitos. Objetivos: Analizar la expresión de CD25 y CD26 en linfocitos T y sus derivados solubles (sCD25 y sCD26) durante asma alérgica moderada-severa y en fases estables. Métodos: Estudio transversal con dos cohortes de adultos con asma alérgica. Se han medido parámetros clínicos, antropométricos, de función pulmonar, hematológicos y bioquímicos. Se ha hecho el fenotipado de leucocitos circulantes y en cultivo mediante citometría de flujo. Se ha analizado la actividad Dipeptidil peptidasa 4 (DPP4) en sobrenadantes de cultivo. Resultados: Los estudios in vitro mostraron un aumento de expresión de CD26 en linfocitos T humanos tras activación, especialmente en condiciones favorables para TH 17, y una correlación con la actividad DPP4 soluble (rs=0,641; p < 0,001). La expresión de CD26 en linfocitos fue mayor en asmáticos, mientras que sCD26 estaba reducido en sueros de mujeres y pacientes. Este último hallazgo podría ser relacionado con la expansión de una subpoblación CD25 low/CD26 low/CD127 low de células T CD4 + efectoras en asma alérgica, sin cambios en los porcentajes de Treg. Sin embargo, las mujeres mostraron un incremento del cociente Tef/Treg, lo cual podría explicar su mayor susceptibilidad al asma. Conclusiones: El asma alérgica causa un incremento de células TH CD25 low CD26 low durante fases no activas. Estos cambios se reflejan en suero y deberían tenerse en cuenta a la luz de la función inhibidora de CD26 sobre quimioquinas importantes relacionadas con la patogénesis del asma, como CCL11 (eotaxina), CCL5 (RANTES) o CXCL12a (SDF-1alfa)
Responsable: ES1.1
BNCS


  4 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Texto completo
Id: 169319
Autor: Cebrián Cuenca, Ana M; Orozco Beltrán, Domingo; Navarro Pérez , Jorge; Álvarez-Guisasola, Fernando; Núñez Villota, Julio; Consuegra-Sánchez, Luciano.
Título: Saxagliptina e insuficiencia cardiaca en el estudio SAVOR-TIMI 53: bajo la lupa de Bradford Hill / Saxagliptin and heart failure in the SAVOR-TIMI 53 Trial: reflections on the Bradford Hill criteria
Fuente: Rev. esp. cardiol. (Ed. impr.);70(12):1143-1144, dic. 2017.
Idioma: es.
Resumen: No disponible
Responsable: ES1.1
BNCS


  5 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Id: 168284
Autor: Detel, Dijana; Buljevic, Suncica; Baticic Pucar, Lara; Kucic, Natalia; Pernjak Pugel, Ester; Varljen, Jadranka.
Título: Influence of CD26/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution
Fuente: J. physiol. biochem;72(3):405-419, sept. 2016. tab, graf, ilus.
Idioma: en.
Resumen: A lot of evidence for the importance of CD26/dipeptidyl peptidase IV (CD26/DPP IV) in immunoactivation has been reported; however, its involvement in colitis remains unclear. The aim of this study was to investigate the influence of CD26/DPP IV deficiency on immunophenotypic changes associated with dextran sulfate sodium (DSS)-induced colitis in wild-type (WT) and CD26-deficient mice. Development of clinical symptoms of colitis and animal health status parameters were assessed; the expression of the nuclear factor (NF)-κB p65 subunit was measured by quantitative real-time PCR, while cell characterization was determined by flow cytometry and immunohistochemical staining. DSS treatment induced loss of body weight and colon length shortening in both mouse strains. An increase of myeloperoxidase activity in CD26-deficient mice was more intensive than in WT mice, in spite of similar histopathological changes. Furthermore, a significant increase in the expression of NF-κB p65 subunit in the colon of CD26-deficient mice was determined. The percentage of splenic CD4+ and CD8+ cells in the acute phase of colitis was significantly decreased in WT mice, while in the same period, an increase in the percentage of splenic CD8+ cells was present in CD26-deficient mice. Development of colitis was accompanied by a significant increase in the percentage of intrahepatic NKT cells in both mouse strains, but their percentage in spleen was increased only in CD26-deficient mice. CD26 deficiency was associated with a heightened response to DSS accompanied by increased expression of NF-κB p65 subunit and distinct changes in leukocyte trafficking. These results provide new insights into the role of CD26/DPP IV during the development of colitis (AU)

No disponible
Responsable: ES1.1
BNCS


  6 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Texto completo
Id: 151912
Autor: Laudo Pardos, Consuelo; Puigdevall Gallego, Víctor.
Título: ¿Qué aportan los nuevos antidiabéticos orales? / What do they offer new oral antibiotics?
Fuente: Aten. prim. (Barc., Ed. impr.);48(5):279-280, mayo 2016.
Idioma: es.
Resumen: No disponible
Responsable: ES1.1
BNCS


  7 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Texto completo
Id: 148664
Autor: Formiga, Francesc; Gómez-Huelgas, Ricardo; Rodríguez Mañas, Leocadio.
Título: Características diferenciales de la diabetes mellitus tipo 2 en el paciente anciano. Papel de los inhibidores de la dipeptidil peptidasa 4 / Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors
Fuente: Rev. esp. geriatr. gerontol. (Ed. impr.);51(1):44-51, ene.-feb. 2016. tab.
Idioma: es.
Resumen: La prevalencia de la diabetes mellitus tipo 2 se incrementa con la edad, alcanzando porcentajes de alrededor del 30% en los mayores de 75 años. La diabetes mellitus tipo 2 en el anciano presenta unas características fisiopatológicas y clínicas distintas a las del paciente diabético más joven. Algunos aspectos diferenciales en esta población son su menor expectativa de vida y la frecuente presencia de comorbilidad, fragilidad y discapacidad. Evitar las hipoglucemias constituye una prioridad terapéutica, dado su mayor riesgo de presentar hipoglucemias graves. Todo ello conforma una situación en la que los beneficios del control intensivo de la glucemia son prácticamente inexistentes y la prevención de los efectos secundarios de los tratamientos se convierte en una prioridad. Por todo ello, los objetivos de control glucémico deberán ser menos estrictos que en la población general (hemoglobina glicada >7%) y los fármacos de elección serán aquellos con bajo riesgo de efectos secundarios (en especial hipoglucemias) y bien tolerados. Los inhibidores de la enzima DPP4 (iDPP4) son fármacos antidiabéticos de especial utilidad en este grupo de edad, bien como fármacos de segunda línea añadidos a la metformina o en monoterapia cuando esta esté contraindicada o no sea tolerada. En el presente artículo se revisa la evidencia disponible sobre la eficacia y tolerancia de las diferentes opciones farmacológicas disponibles en población mayor de 70 años (AU)

The prevalence of type 2 diabetes mellitus increases with age, reaching rates around 30% in those over 75 years. The type 2 diabetes mellitus in the elderly has different pathophysiological and clinical characteristics from those of the younger diabetic patient. Some differential aspects in this population are the lower life expectancy and the frequent comorbidity, frailty and associated disability. Avoiding hypoglycemia is a therapeutic priority, given their increased risk of severe hypoglycemia. It is a situation in which the benefits of intensive glycemic control are virtually non-existent, thus prevention of side effects of treatments becomes a priority. Therefore, the goals of glycemic control should be less stringent than in the general population (glycated hemoglobin > 7%), and the drugs of choice should be those with a low risk of side effects (especially hypoglycemia) and well tolerated. Dipeptidyl peptidase 4 inhibitors (iDPP4) are particularly useful in this age group, either as a second drug added to metformin monotherapy, or as first line when metformin is contraindicated or not tolerated. In this article the evidence available on the efficacy and tolerance of different pharmacological options available in population over 70 years is reviewed (AU)
Responsable: ES1.1
BNCS


  8 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Id: 141492
Autor: Ampudia-Blasco, Francisco Javier; Ceriello, Antonio.
Título: Importancia de la variabilidad del control glucémico diario en la consecución de los objetivos de control en la diabetes mellitus tipo 2: papel de los inhibidores de la dipeptidil peptidasa 4 / Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors
Fuente: Med. clín (Ed. impr.);135(supl.2):33-39, sept. 2010. tab, graf.
Idioma: es.
Resumen: La diabetes tipo 2 se caracteriza por la presencia de hiperglucemia tanto posprandial como en ayuno. La hemoglobina glucosilada es un marcador de la exposición glucémica global e integra la hiperglucemia tanto en ayunas como posprandial. Los estudios epidemiológicos y de intervención en diabetes tipo 2 y tipo 1 han demostrado que la hiperglucemia crónica está asociada con la aparición de complicaciones diabéticas crónicas. Más importante aún es el hecho de que la reducción de la hemoglobina glucosilada, con el fin de alcanzar el objetivo diana, previene y evita la progresión de las complicaciones, en particular, en los eventos microvasculares. Aunque la hiperglucemia crónica produce una glicación de proteínas excesiva, las fluctuaciones agudas de la glucosa pueden activar el estrés oxidativo y contribuir a la disfunción endotelial, lo que también podría estar implicado en el desarrollo de las complicaciones por diabetes. Por consiguiente, la reducción de la hiperglucemia posprandial y de las variaciones glucémicas se reconoce ahora como una prioridad en el tratamiento de la diabetes tipo 2. Los agentes terapéuticos que actúan sobre la glucosa posprandial son particularmente de interés para disminuir las variaciones glucémicas. Los nuevos agentes terapéuticos, los agonistas del péptido 1 similar al glucagón y los inhibidores de la dipeptidil peptidasa 4 (DPP), son interesantes. Ambos aumentan la secreción de insulina e inhiben la liberación de glucagón como respuesta a una comida de un modo que es dependiente de la glucosa. Este artículo se centrará en la creciente repercusión de la hiperglucemia posprandial y de las variaciones glucémicas en el desarrollo de complicaciones por diabetes y el papel de los inhibidores de la DPP-4 (sitagliptina, vildagliptina, saxagliptina) a la hora de reducir ambos defectos en las personas con diabetes tipo 2 (AU)

Type 2 diabetes is characterized by the presence of both fasting and postprandial hyperglycaemia. Glycated haemoglobin is a marker of overall glycaemic exposure and integrates both fasting and postprandial hyperglycaemia. Epidemiologic and interventional studies in type 1 and type 2 diabetes have demonstrated that chronic hyperglycaemia is associated with the appearance of chronic diabetes complications. More importantly, reducing glycated haemoglobin to achieve target goals prevents and avoid progression of complications, in particular microvascular outcomes. Although sustained chronic hyperglycaemia produces excessive protein glycation, acute fluctuations of glucose may activate oxidative stress and contribute to endothelial dysfunction, which may also participate in the development of diabetes complications. Therefore, reducing postprandial hyperglycaemia and glucose variability are now recognised as a priority in treatment of type 2 diabetes. Therapeutic agents acting on postprandial glucose excursions are of particular interest to diminish glucose variability. Emerging therapeutic agents such as the glucagon-like peptide 1 agonists and the dipeptidyl peptidase (DPP)-4 inhibitors are very attractive. Both increase insulin secretion and suppress glucagon release in response to meals, in a glucose-dependent manner. This review will focus on the increasing impact of postprandial hyperglycaemia and glycaemic variability in developing diabetes complications and the role of DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) in reducing both defects presenting in people with type 2 diabetes (AU)
Responsable: ES1.1
BNCS


  9 / 18 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Fotocópia
Id: 136386
Autor: Escalada, Francisco Javier.
Título: Fisiología del GLP-1 y su papel en la fisiopatología de la diabetes mellitus tipo 2 / The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus
Fuente: Med. clín (Ed. impr.);143(supl.2):2-7, sept. 2014.
Idioma: es.
Resumen: El péptido similar al glucagón-1 (GLP-1) es una hormona intestinal sintetizada en las células L intestinales cuya secreción depende de la presencia de nutrientes en la luz del intestino delgado. Una vez que el GLP-1 alcanza la circulación, tiene una vida media de unos pocos minutos, debido a la rápida degradación por parte de la enzima dipeptidil peptidasa-4 (DPP-4). Su función fisiológica se fundamenta en el control de la concentración sanguínea de glucosa, aunque desempeña múltiples funciones en la homeostasis metabólica después de la absorción de nutrientes. Las actividades biológicas del GLP-1 incluyen la estimulación de la secreción de insulina dependiente de la glucosa y la biosíntesis de insulina, la inhibición de la secreción de glucagón y del vaciado gástrico, y la inhibición de la ingesta de alimentos. El hallazgo de que el GLP-1 reduce los niveles plasmáticos de glucosa en pacientes con diabetes mellitus, junto con otros datos que sugieren que el GLP-1 puede restaurar la sensibilidad de las células beta a secretagogos exógenos, sugiere que aumentar la señalización del GLP-1 es una estrategia útil para el tratamiento de pacientes con diabetes mellitus tipo 2 (AU)

The hormone glucagon-like peptide-1 (GLP-1) is synthesized and secreted by L cells in the small intestine in response to food ingestion. After reaching the general circulation it has a half-life of 2-3 minutes due to degradation by the enzyme dipeptidyl peptidase-4. Its physiological role is directed to control plasma glucose concentration, though GLP-1 also plays other different metabolic functions following nutrient absorption. Biological activities of GLP-1 include stimulation of insulin biosynthesis and glucose-dependent insulin secretion by pancreatic beta cell, inhibition of glucagon secretion, delay of gastric emptying and inhibition of food intake. GLP-1 is able to reduce plasma glucose levels in patients with type 2 diabetes and also can restore beta cell sensitivity to exogenous secretagogues, suggesting that the increasing GLP-1 concentration may be an useful therapeutic strategy for the treatment of patients with type 2 diabetes (AU)
Responsable: ES1.1
BNCS


  10 / 18 IBECS  
              first record previous record
selecciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Id: 121993
Autor: Potrich Bellé, Luziane; Rodrigues Bitencourt, Paula Eliete; Husein Abdalla, Faida; Santos de Bona, Karine; Moretto, Maria Beatriz; Konzen Maders, Liési Diones; Peres , Alessandra.
Título: Aqueous seed extract of Syzygium cuminiinhibits the dipeptidyl peptidase IV and adenosine deaminase activities, but it does not change the CD26 expression in lymphocytes in vitro
Fuente: J. physiol. biochem;69(1):119-124, mar. 2013.
Idioma: en.
Resumen: Syzygium cumini (Sc) have been intensively studied in the last years due its beneficial effects including anti-diabetic and anti-inflammatory potential. Thus, the aim of this study was to evaluate the effect of aqueous seed extract of Sc (ASc) in the activity of enzymes involved in lymphocyte functions. To perform this study, we isolated lymphocytes from healthy donors. Lymphocytes were exposed to 10, 30, and 100 mg/mL of ASc during 4 and 6 h and adenosine deaminase (ADA), dipeptidyl peptidase IV (DPP-IV), and acetylcholinesterase (AChE) activities as well as CD26 expression and cellular viability were evaluated. ASc inhibited the ADA and DPP-IV activities without alteration in the CD26 expression (DPP-IV protein). No alterations were observed in the AChE activity or in the cell viability. These results indicate that the inhibition of the DPP-IV and ADA activities was dependent on the time of exposition to ASc. We suggest that ASc exhibits immunomodulatory properties probably via the pathway of DPP-IVûADA complex, contributing to the understanding of these proceedings in the purinergic signaling (AU)
Responsable: ES1.1
BNCS



página 1 de 2 va a la página        
   


Refinar la búsqueda
  Base de datos : Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud